We focus on companies with strong underlying technologies and exceptional founders, anywhere in the world.
Portfolio

Harnessing directed evolution to improve antibody-drug conjugate internalization and trafficking.
(exit)

Simplifying complex care with an AI-enabled platform to automate hospital workflows and optimize use of resources.
(exit)

High throughput wet lab and ML platform for screening, building, and delivering fully-assembled modular cell-therapies.
(exit)

Empowers businesses with scalable AI-driven solutions to optimize decision-making and drive innovation.
(exit)

Fuelling athletes with long lasting energy powered by high quality and sustainable ingredients.
(exit)

Rethinking liver therapy discovery and development by using human models to generate data at scale.
(exit)

Marketplace for sustainability and traceability of food commodities, starting with palm fruit.
(exit)

Simplifying the labor-intensive process of collecting, organizing, and inspecting vast amounts of complex data.
(exit)

Helping you discover genetic predispositions and personalized health suggestions based on DNA and labs.
(exit)

Enabling the next generation of consumer audio with high-performance MEMS directional microphones.
(exit)

Develops a social community platform that connects investors and traders across various asset classes, allowing them to share insights, track portfolios, and receive real-time market alerts
(exit)

Providing scalable architecture for real-time stock, crypto and international market data streaming.
(exit)

Delivering hyper-personalized digital experiences based on the science behind consumer behaviour.
(exit)

Leveraging synthetic biology to develop multimodal nanofilament therapeutics to locally engage the immune system for unparalleled tumor clearance.
(exit)

Developers of the first platform to target previously “undruggable” transcription factors in their native cellular environments.
(exit)

Develops a video platform that connects people through customizable group chats, workshops, and private conversations
(exit)

Transforming the paradigm of rare disease drug development by clinically derisking new targets using existing drugs.
(exit)
.png)
Developing high-throughput assays to discover small-molecule drugs targeting under-drugged human enzymes.
(exit)